Histone Acetyltransferase
HATs; HAT
Histone acetyltransferases (HATs) are epigenetic enzymes that install acetyl groups onto lysine residues of cellular proteins such as histones, transcription factors, nuclear receptors, and enzymes. HATs are crucial for chromatin restructuring and transcriptional regulation in eukaryotic cells. HATs have been shown to play a role in diseases ranging from cancer and inflammatory diseases to neurological disorders, both through acetylations of histone proteins and non-histone proteins.
HATs can be grouped into at least five different subfamilies (HAT1, Gcn5/PCAF, MYST, p300/CBP, and Rtt109). HATs mediate many different biological processes including cell-cycle progression, dosage compensation, repair of DNA damage, and hormone signaling. Aberrant HAT function is correlated with several human diseases including solid tumors, leukemias, inflammatory lung disease, viral infection, diabetes, fungal infection, and drug addiction.
Histone Acetyltransferase Isoform Specific Products
All Product Categories
-
Histone Acetyltransferase Inhibitors
(185)
View all products
-
Histone Acetyltransferase Agonist
(1)
View all products
-
Histone Acetyltransferase Activators
(13)
View all products
-
Histone Acetyltransferase Modulators
(3)
View all products
-
Histone Acetyltransferase Degraders
(39)
View all products
-
Histone Acetyltransferase Controls
(5)
View all products
-
Histone Acetyltransferase Substrates
(5)
View all products
-
Histone Acetyltransferase Ligands
(11)
View all products
-
Histone Acetyltransferase Related Products (289)
Related Products (289)
-
Antibodies (25)
-
Histone Acetyltransferase Isoform Comparison
-
KAT6-IN-4
0 ImagesCat. No.: HY-177445CAS No.: 2901797-38-2KAT6-IN-4 (Compound Example 2) is a selective lysine acetyltransferase 6 (KAT6) inhibitor. KAT6-IN-4 suppresses transcription of oncogenes like ERα. KAT6-IN-4 demonstrates potent antitumor efficacy in ER+/HER2- breast cancer xenografts. KAT6-IN-4 is promising for research of KAT6-driven malignancies (e.g., breast cancer, NSCLC).
-
Pomalidomide-NH-PEG6-amide-C2-CPI-1612
0 ImagesCat. No.: HY-161250Pomalidomide-NH-PEG6-amide-C2-CPI-1612 is a CBP/EP300 PROTAC degrader with a DC50 value of 1.3 μM. Pomalidomide-NH-PEG6-amide-C2-CPI-1612 mediates the formation of a ternary complex between CRBN and the core of CBP, with an EC50 of 1.2 μM. Pomalidomide-NH-PEG6-amide-C2-CPI-1612 inhibits cancer cell growth and exhibits cell line-specific degradation activity. Pomalidomide-NH-PEG6-amide-C2-CPI-1612 can be used in research related to multiple myeloma and leukemia.
-
HAT-IN-1
0 ImagesCat. No.: HY-103669CAS No.: 1889281-94-0HAT-IN-1 is an inhibitor of HAT, used in the research of cancer.
-
(E/Z)-NiCur
0 ImagesCat. No.: HY-139149ACAS No.: 63476-70-0(E/Z)-NiCur is the active isomer of NiCur (HY-139149). (E/Z)-NiCur is a potent CBP histone acetyltransferase (HAT) inhibitor.
-
Ep300/CREBBP-IN-8
0 ImagesCat. No.: HY-128362CAS No.: 2259641-24-0Ep300/CREBBP-IN-8 (Example 37) is a potent and orally active Ep300 and CREBBP inhibitor with IC50s of 0.014 and 0.018 μM, respectively. Ep300/CREBBP-IN-8 can be used for the research of cancer.
-
CCT077791
0 ImagesCat. No.: HY-121009CAS No.: 748777-47-1CCT077791 is a PCAF (IC50: 7.3 μM (FlashPlate); 2.2 μM (Filter assay)) and p300 histone acetyltransferase inhibitor. CCT077791 reduces total acetylation of histones H3 and H4, levels of specific acetylated lysine marks, and acetylation of α-tubulin. CCT077791 can be used in the research of colorectal cancer.
-
CBP/p300-IN-22
0 ImagesCat. No.: HY-176251CBP/p300-IN-22 is a selective CBP/EP300-BRD inhibitor with an IC50 of 4 nM. CBP/p300-IN-22 is highly selective over BRD4(1). CBP/p300-IN-22 reduces TNF-α-induced cytokine expression and subsequent immune cell recruitment by inhibiting NF-κB signaling, and has anticancer activity. CBP/p300-IN-22 can be used for the research of rheumatoid arthritis (RA) and other TNF-α-mediated inflammatory conditions.
-
KAT5 Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS07080KAT5 Human Pre-designed siRNA Set A contains three designed siRNAs for KAT5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
CBP/p300-IN-19
0 ImagesCat. No.: HY-146277CAS No.: 2592638-13-4CBP/p300-IN-19 is a potent p300/CBP HAT inhibitor with IC50s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 shows antitumor activity.
-
ARHB
0 ImagesCat. No.: HY-D2983CAS No.: 2310262-15-6ARHB is a highly selective and sensitive NAT2 fluorescent probe suitable for real-time detection of NAT2 activity in various bacteria. ARHB can successfully penetrate the bacterial cells, and the fluorescence intensity is positively correlated with the expression level of NAT2. ARHB is used for high-throughput screening of natural inhibitors for tuberculosis.
-
dCE-2
0 ImagesCat. No.: HY-161958dCE-2 is a CBP/EP300 PROTAC degrader with a DC50 of 40 nM against CBP. dCE-2 forms a ternary complex with the bromodomains of CBP/EP300 and the CRBN E3 ligase, driving proteasomal degradation of CBP/EP300 via positive cooperativity. dCE-2 is applicable to research related to multiple myeloma, prostate cancer, and neuroblastoma.
-
CTB (Standard)
0 ImagesCTB (Standard) is the analytical standard of CTB. This product is intended for research and analytical applications. CTB is a potent p300 histone acetyltransferase activator. CTB can effectively induce apoptosis in MCF-7 cells.
-
Remodelin (Standard)
0 ImagesCat. No.: HY-16706RCAS No.: 949912-58-7Remodelin (Standard) is the analytical standard of Remodelin (HY-16706). This product is intended for research and analytical applications. Remodelin is an orally active and selective inhibitor of acetyltransferase NAT10. Remodelin inhibits NAT10 activitity and slows DNA replication and suppresses growth of prostate cancer cells. Remodelin inhibits the growth of prostate cancer and hepatocellular carcinoma in xenograft model. Remodelin enhances the healthspan in hutchinson-gilford progeria syndrome (HGPS) mouse model.
-
GSK 4027 (Standard)
0 ImagesCat. No.: HY-101027RCAS No.: 2079896-25-4GSK 4027 (Standard) is the analytical standard of GSK 4027 (HY-101027). This product is intended for research and analytical applications. GSK 4027 is a chemical probe for the PCAF/GCN5 bromodomain with an pIC50 of 7.4±0.11 for PCAF in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.
-
4-Aminonaphthalen-1-yl acetate
0 ImagesCat. No.: HY-W614583CAS No.: 858186-27-34-Aminonaphthalen-1-yl acetate is a 4-amino-1-naphthol derivative and a negative control reagent for lysine (K) acetyltransferase KAT8. 4-Aminonaphthalen-1-yl acetate shows no activity against KAT8.
-
NSC 228155 (Standard)
0 ImagesCat. No.: HY-101084RCAS No.: 113104-25-9NSC 228155 (Standard) is the analytical standard of NSC 228155 (HY-101084). This product is intended for research and analytical applications. NSC 228155 is an activator of EGFR, binds to the extracellular region of EGFR and enhance tyrosine phosphorylation of EGFR. NSC 228155 is also a potent inhibitor of KIX-KID interaction, inhibits kinase-inducible domain (KID) from CREB and KID-interacting domain (KIX) from CBP, with an IC50 of 0.36 μM.
-
L002 (Standard)
0 ImagesL002 (Standard) is the analytical standard of L002 (HY-100671). This product is intended for research and analytical applications. L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an IC50 of 1.98 μM. L002 binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain, blocks histone acetylation and p53 acetylation, and inhibits STAT3 activation. L002 has the potential for hypertension-induced cardiac hypertrophy and fibrogenesis treatment.
-
WIZ degrader 7
0 ImagesCat. No.: HY-163824CAS No.: 3036553-83-7WIZ degrader 7 (Example 16) is a WIZ molecular glue degrader with an IC50 value of < 0.01 μM. WIZ degrader 7 can be used to investigate sickle cell disease (SCD) and thalassemia.
